Breakthrough Therapy Designation based on updated data from Phase 2 MagnetisMM-3 study that showed an overall response rate of 61.0% and a manageable safety profile after a median follow-up of 6.8 months
Data to be presented at the 64th American Society of Hematology Annual Meeting and Exposition 2022 (ASH 2022)
